SLC5A2 and cardiovascular disorder: SGLT2 inhibitors have become a fundamental aspect of managing T2DM, particularly in patients with existing cardiovascular disease or heart failure, due to their significant ability to reduce major adverse cardiovascular events and heart failure events.